Published in Proc Natl Acad Sci U S A on July 18, 2006
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells (2009) 4.08
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One (2008) 3.36
Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells. Cell Stem Cell (2016) 2.69
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res (2011) 2.50
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer (2008) 2.28
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2.20
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2011) 2.03
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer (2010) 1.85
Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin (2013) 1.83
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 1.81
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood (2011) 1.76
Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res (2008) 1.75
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol (2012) 1.75
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 1.68
TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br J Cancer (2010) 1.65
Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res (2010) 1.52
Stem cells and the pathogenesis of endometriosis. Ann N Y Acad Sci (2008) 1.49
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev (2010) 1.46
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther (2009) 1.43
Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci U S A (2008) 1.41
Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med (2007) 1.38
Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett (2012) 1.38
MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J (2009) 1.37
Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling. PLoS One (2010) 1.33
Cancer stem cells in head and neck squamous cell carcinoma. J Oncol (2010) 1.31
Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin Cancer Res (2009) 1.31
Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol (2008) 1.28
Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer (2013) 1.27
Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer (2012) 1.27
The biology of head and neck cancer stem cells. Oral Oncol (2011) 1.25
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J (2010) 1.25
Epithelial ovarian cancer experimental models. Oncogene (2013) 1.23
Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer (2009) 1.22
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A (2012) 1.21
Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom (2010) 1.21
Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A (2010) 1.20
Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res (2009) 1.19
Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One (2012) 1.18
Flow cytometric determination of stem/progenitor content in epithelial tissues: an example from nonsmall lung cancer and normal lung. Cytometry A (2012) 1.18
Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res (2008) 1.18
Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol (2008) 1.18
Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells. BMC Cancer (2008) 1.15
Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene (2012) 1.13
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Exp Clin Cancer Res (2013) 1.13
Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain (2013) 1.12
TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle (2013) 1.12
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal (2009) 1.11
Advances in complex multiparameter flow cytometry technology: Applications in stem cell research. Cytometry B Clin Cytom (2009) 1.10
Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS One (2013) 1.09
Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J Control Release (2007) 1.09
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer (2012) 1.09
Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res (2008) 1.08
The role of microRNAs in ovarian cancer initiation and progression. J Cell Mol Med (2010) 1.08
Breast cancer, side population cells and ABCG2 expression. Cancer Lett (2012) 1.07
The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics. Oncotarget (2014) 1.06
Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res (2010) 1.06
Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Curr Protoc Pharmacol (2009) 1.06
Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics (2010) 1.05
Cancer stem cells in solid tumors: elusive or illusive? Cell Commun Signal (2010) 1.05
Ovarian cancer stem cells: are they real and why are they important? Gynecol Oncol (2013) 1.04
Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A (2014) 1.04
Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN. PLoS One (2011) 1.04
Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn (2015) 1.04
ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One (2013) 1.03
Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res (2011) 1.02
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol (2013) 1.02
ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle (2009) 1.01
Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. Int J Oncol (2012) 1.00
Gastric carcinogenesis and the cancer stem cell hypothesis. Gastric Cancer (2010) 1.00
TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis. Oncotarget (2014) 0.99
Head and neck cancer stem cells: the side population. Laryngoscope (2010) 0.98
Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res (2010) 0.98
Cardiac side population cells: moving toward the center stage in cardiac regeneration. Circ Res (2012) 0.98
Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells. ACS Nano (2014) 0.97
Stem cells and female reproduction. Reprod Sci (2009) 0.96
Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp (Warsz) (2008) 0.95
Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovarian Res (2008) 0.95
Bmi-1: At the crossroads of physiological and pathological biology. Genes Dis (2015) 0.95
Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol (2010) 0.95
Colon cancer stem cells: controversies and perspectives. World J Gastroenterol (2013) 0.95
Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci (2013) 0.95
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol (2010) 0.95
Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention. Mol Cancer (2014) 0.94
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia (2010) 0.93
Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells. J Biol Chem (2009) 0.93
Clinical significance of side population in ovarian cancer cells. Hum Cell (2011) 0.93
Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment. World J Gastroenterol (2014) 0.92
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med (1996) 17.51
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods (1986) 12.51
Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem (1993) 10.95
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A (2004) 6.84
Stem cell niche: structure and function. Annu Rev Cell Dev Biol (2005) 5.33
Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A (2004) 5.32
Cancer statistics, 1997. CA Cancer J Clin (1997) 5.22
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
Cancer of the ovary. N Engl J Med (1993) 4.53
Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells (2005) 3.66
Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol (2004) 3.41
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene (2003) 3.12
Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res (2003) 3.04
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood (2001) 2.71
Cancer stem cell characteristics in retinoblastoma. Mol Vis (2005) 1.77
Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74
Will cancer stem cells provide new therapeutic targets? Carcinogenesis (2004) 1.64
Origin of germ cells and formation of new primary follicles in adult human ovaries. Reprod Biol Endocrinol (2004) 1.48
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer (1990) 1.35
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther (2004) 1.34
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol (2004) 1.33
Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc Natl Acad Sci U S A (1982) 1.31
Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem (2000) 1.31
Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression. Development (2006) 1.26
An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab (1990) 1.26
On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis (1982) 1.25
Recent progress in ovarian cancer. Hum Pathol (1970) 1.22
Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res (2002) 1.15
Lineage-negative side-population (SP) cells with restricted hematopoietic capacity circulate in normal human adult blood: immunophenotypic and functional characterization. Stem Cells (2002) 1.14
Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann N Y Acad Sci (1956) 1.14
A graded organ culture assay for the detection of Mullerian inhibiting substance. J Surg Res (1977) 1.13
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res (2006) 1.02
New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.00
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol (2002) 0.99
Leukemia: stem cells, preleukemia and cure. Leukemia (1992) 0.98
The production of Mullerian inhibiting substance by the fetal, neonatal and adult rat. Biol Reprod (1976) 0.92
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol Oncol (1985) 0.91
A brief history of the pathology of the gonads. Mod Pathol (2005) 0.88
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03
Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med (2005) 4.17
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (2007) 3.62
A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci U S A (2008) 3.57
Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol (2011) 3.25
Sex determination and differentiation. N Engl J Med (2004) 3.07
CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells (2009) 2.76
Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood (2002) 2.66
A biodegradable and biocompatible gecko-inspired tissue adhesive. Proc Natl Acad Sci U S A (2008) 2.58
Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med (2013) 2.48
Global expression analysis of gene regulatory pathways during endocrine pancreatic development. Development (2003) 2.39
Nonoperative management of perianal abscess in infants is associated with decreased risk for fistula formation. Pediatrics (2007) 2.20
Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol (2005) 2.07
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther (2006) 1.88
Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet (2007) 1.85
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res (2006) 1.84
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 1.81
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila) (2009) 1.75
Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther (2007) 1.54
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil Steril (2007) 1.51
HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A (2009) 1.45
Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. Am J Physiol Cell Physiol (2004) 1.43
Endovascular stenting of a penetrating axillary artery injury in a 14-year-old with 1-year follow-up. J Pediatr Surg (2009) 1.41
Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci U S A (2008) 1.41
P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. Genes Dev (2003) 1.41
Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation (2003) 1.36
Dissecting spatio-temporal protein networks driving human heart development and related disorders. Mol Syst Biol (2010) 1.35
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res (2006) 1.32
Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression. Development (2006) 1.26
The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Front Biosci (2004) 1.25
Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol (2005) 1.22
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res (2006) 1.22
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A (2012) 1.21
Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom (2010) 1.21
Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A (2010) 1.20
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A (2010) 1.20
Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells (2007) 1.18
Management and long-term follow-up of patients with types III and IV laryngotracheoesophageal clefts. J Pediatr Surg (2005) 1.17
Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics (2008) 1.17
Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One (2009) 1.17
Matrix metalloproteinase-9-deficient dendritic cells have impaired migration through tracheal epithelial tight junctions. Am J Respir Cell Mol Biol (2003) 1.15
Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res (2002) 1.15
Lineage-negative side-population (SP) cells with restricted hematopoietic capacity circulate in normal human adult blood: immunophenotypic and functional characterization. Stem Cells (2002) 1.14
Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci U S A (2005) 1.14
MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol Cell Endocrinol (2003) 1.11
Chick pulmonary Wnt5a directs airway and vascular tubulogenesis. Development (2008) 1.10
Advances in complex multiparameter flow cytometry technology: Applications in stem cell research. Cytometry B Clin Cytom (2009) 1.10
Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc Natl Acad Sci U S A (2012) 1.08
Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci (Landmark Ed) (2011) 1.08
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol (2007) 1.07
Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene. Birth Defects Res A Clin Mol Teratol (2003) 1.07
Infants with Bochdalek diaphragmatic hernia: sibling precurrence and monozygotic twin discordance in a hospital-based malformation surveillance program. Am J Med Genet A (2005) 1.06
Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle (2007) 1.04
GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharmacol (2005) 1.03
p190A RhoGAP is a glycogen synthase kinase-3-beta substrate required for polarized cell migration. J Biol Chem (2008) 1.03
Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A (2012) 1.03
Extracorporeal membrane oxygenation for nonneonatal acute respiratory failure: the Massachusetts General Hospital experience from 1990 to 2008. Arch Surg (2009) 1.03
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res (2006) 1.02
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Intersex genetic anomalies with malignant potential. Curr Opin Pediatr (2006) 1.01
Congenital diaphragmatic hernia candidate genes derived from embryonic transcriptomes. Proc Natl Acad Sci U S A (2012) 1.01
IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin. Exp Mol Pathol (2004) 1.01
Cervical spine injury in young children: a National Trauma Data Bank review. J Pediatr Surg (2008) 1.01
8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol (2007) 1.00
New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.00
Congenital diaphragmatic hernia (CDH) etiology as revealed by pathway genetics. Am J Med Genet C Semin Med Genet (2007) 0.99
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci U S A (2002) 0.99
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc Natl Acad Sci U S A (2004) 0.99
Late complications of newborn circumcision: a common and avoidable problem. Pediatr Surg Int (2010) 0.99
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A (2003) 0.98
Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens. Endocrinology (2003) 0.98
Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One (2011) 0.97
Donnai-Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete chromosome 2 paternal isodisomy. Am J Med Genet A (2008) 0.96
MEK-1/2 inhibition reduces branching morphogenesis and causes mesenchymal cell apoptosis in fetal rat lungs. Am J Physiol Lung Cell Mol Physiol (2002) 0.96
Endothelial cells promote migration and proliferation of enteric neural crest cells via beta1 integrin signaling. Dev Biol (2009) 0.95
Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol (2010) 0.95
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol (2010) 0.95
Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium. Reprod Sci (2009) 0.92
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology (2007) 0.92
Ephrin receptor, EphB4, regulates ES cell differentiation of primitive mammalian hemangioblasts, blood, cardiomyocytes, and blood vessels. Blood (2003) 0.92